Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity
View abstract on PubMed
Summary
This summary is machine-generated.Gene therapy using Interleukin 12 (IL12) effectively reduced pancreatic cancer spread in mice. This treatment activated the immune system, particularly M1 macrophages, to fight tumors with no observed toxicity.
Area Of Science
- Oncology
- Immunotherapy
- Gene Therapy
Background
- Pancreatic cancer with peritoneal carcinomatosis has a poor prognosis.
- Effective treatments are lacking.
- Interleukin 12 (IL12) shows potential antitumoral effects by boosting immunity.
Purpose Of The Study
- To evaluate the efficacy and safety of intraperitoneal Interleukin 12 (IL12) delivery via ex vivo gene therapy.
- To assess the treatment in a murine model of pancreatic peritoneal carcinomatosis.
Main Methods
- Pancreatic peritoneal carcinomatosis was induced in athymic mice.
- Syngenic fibroblasts were genetically modified to secrete IL12.
- Ex vivo gene therapy involved intraperitoneal injections of modified fibroblasts over 4 weeks.
Main Results
- IL12-expressing fibroblasts significantly inhibited tumor growth and improved survival.
- Treatment led to increased macrophage and natural killer cell infiltration.
- Activated M1 macrophages showed enhanced proinflammatory and antitumoral activity.
Conclusions
- Intraperitoneal delivery of IL12 via genetically modified fibroblasts is a promising treatment for pancreatic peritoneal carcinomatosis.
- The therapy activates innate immunity, particularly M1 macrophages.
- The approach demonstrated effectiveness and good tolerability in the experimental model.